Key facts, as of
As of October 8, 2026, Bio-Techne Corporation (TECH) trades at $72.53, up 22.5% over the past year. It is at the top of its 52-week range ($43.20 to $72.69). It is 46.7% below its all-time high of $135.96, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +180.8%, against +312.9% for the S&P 500 (SPY). It sits 16.5% above its 200-day average of $62.27, the usual sign of a long-term uptrend. Its 30-day volatility is 2.1% annualized, which we rate low risk. It has a trailing P/E of 62.5 and a dividend yield of 0.44%.
Cite: Portfolio Terminal, "Bio-Techne Corporation (TECH) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/tech
Where it trades today
trading 99% of the way up its 52-week range
How the price has moved
How far it is from its record
Bio-Techne Corporation (TECH) is 46.7% below its all-time high of $135.96, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +180.8%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- TECH trades at 62.5x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility sits near 2.1%, below the sector norm of 22.0%, which supports a steadier role inside a diversified portfolio.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- TECH is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in TECH.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for TECH come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for TECH. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Bio-Techne Corporation does
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow…
What analysts expect
TECH carries a hold consensus from 10 analysts, with an average price target of $70.50 versus $72.53 today (-2.8%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
TECH generated $1.22B in trailing revenue (1.3% year over year), with a 15.0% net margin, and $229.65M of free cash flow, against $23.61M of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2026 | $1.22B | $799.07M | $272.61M | $181.86M | $1.17 | $263.22M |
| 2025 | $1.22B | $790.27M | $242.80M | $73.40M | $0.47 | $256.55M |
| 2024 | $1.16B | $769.73M | $246.40M | $168.10M | $1.07 | $236.10M |
| 2023 | $1.14B | $769.82M | $291.00M | $285.26M | $1.81 | $216.15M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
TECH is in 5 of the 30 ETFs we track. It weighs most in XLV: 0.18% of the fund, holding #54 of 62.
Famous investors who hold it
TECH is in the latest 13F of 1 of the 15 famous investors we follow. George Soros (Soros Fund Management) holds the most of it: 0.46% of the portfolio, position #65 of 261, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
TECH beside the healthcare names it is usually measured against.
What the chart is saying
Trading at its high for the year, with no resistance overhead.
uptrend- Price is 0.3% above its 50-day average and 16.5% above its 200-day.
- The 50-day crossed above the 200-day on 2026-07-24 (a “golden cross”).
- RSI at 58 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $70.55 (-2.7%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is TECH a good investment in 2026?
Bio-Techne Corporation trades at a P/E ratio of 62.5, with low volatility (2.1% annualized). The stock is in a consolidation phase.
What is the risk level of TECH?
Based on 30-day volatility of 2.1%, TECH has LOW risk. Beta of 1.29 indicates higher sensitivity to market movements than average.
Does TECH pay dividends?
Yes, Bio-Techne Corporation has a dividend yield of 0.44%.
How far is TECH from its all-time high?
Bio-Techne Corporation is 46.7% below its all-time high of $135.96, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +180.8%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold TECH?
5 of the 30 popular ETFs we track hold Bio-Techne Corporation. The largest weights: XLV (0.18%), SPY (0.02%), IVV (0.02%), VOO (0.02%) and VTI (0.02%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is TECH?
0.02%, as of August 31, 2026: TECH is holding #470 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.17 in Bio-Techne Corporation.
Which famous investors own TECH?
George Soros (0.46% of Soros Fund Management's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for TECH?
The average analyst price target for Bio-Techne Corporation (TECH) is $70.50 based on 10 analyst estimates, about 2.8% below the current price of $72.53. The published range runs from $50.00 to $73.00.
How much revenue does TECH generate?
Bio-Techne Corporation reported $1.22B in trailing twelve-month revenue. Revenue growth is running at 1.3% year over year. Net margin sits at 15.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare TECH with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.